无血性
安慰剂
重性抑郁障碍
内科学
评定量表
临床全球印象
萧条(经济学)
随机对照试验
临床终点
心理学
汉密尔顿抑郁量表
医学
精神科
精神分裂症(面向对象编程)
心情
病理
经济
替代医学
宏观经济学
发展心理学
作者
S. Benedetto,Adrian Ionescu,Tingting Ge,Maura Furey,Swan Lin,Manish K. Jha,Andrew D. Krystal,Asim A. Shah,David P. Walling,Neel Shah,Sakina J. Rizvi,Sidney H. Kennedy,Antonio Laurenza,Naga Venkatesha Murthy,Eiry Roberts,Jaskaran B. Singh
标识
DOI:10.1097/jcp.0000000000002046
摘要
BACKGROUND: Anhedonia is a core symptom of major depressive disorder (MDD) that may result from aberrant lateral habenula hyperactivity. Targeting G-protein coupled receptor 139 (GPR139) may improve anhedonia by modulating lateral habenula activity. NBI-1065846 is an investigational GPR139 agonist that improved anhedonia, anxiety, and depression in rodent models. METHODS: TERPSIS was a phase 2, proof-of-concept clinical study. Adults with MDD experiencing a major depressive episode with anhedonia were randomized 1:1 to NBI-1065846 or placebo for 8 weeks. The primary endpoint was the change in the Dimensional Anhedonia Rating Scale (DARS) score. Secondary endpoints were change in total Montgomery Åsberg Depression Rating Scale (MADRS) score in participants with a baseline 17-item Hamilton Depression Rating Scale (HAM-D17) score of ≥19 (moderate to severe) and change in Clinical Global Impression of Severity (CGI-S) score. All changes were from baseline to Day 57. RESULTS: In total, 93 participants received study treatment (NBI-1065846, n = 46; placebo, n = 47). Both groups showed notable improvements in DARS scores from baseline to day 57 (least-squares mean change: NBI-1065846, 13.5; placebo, 17.4), with no statistically significant difference (NBI-1065846 vs. placebo, P = 0.8663). Similarly, MADRS ( P = 0.7008) and CGI-S ( P = 0.9051) scores showed no significant difference between groups. All treatment-emergent adverse events in the NBI-1065846 group were mild or moderate in severity. CONCLUSIONS: The TERPSIS study did not meet its primary or secondary endpoints. NBI-1065846 was generally well tolerated. Addressing the lack of treatment options for anhedonia remains an important unmet clinical need.
科研通智能强力驱动
Strongly Powered by AbleSci AI